Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | GUCY1A1 | Q02108 | 4/20 | 0.35 |
| ▸ | GUCY1B1 | Q02153 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140398 | 0.85 | CYP19A1 (0.34) | ARGUCY1A1GUCY1B1KCNH2L3MBTL1 | |
| SCHEMBL14746744 | 0.81 | ALDH1A1 (0.36) | ARL3MBTL1TDP1PDE5ATP53 | |
| SCHEMBL20140419 | 0.79 | GUCY1A1 (0.37) | ARGUCY1A1GUCY1B1KCNH2L3MBTL1 | |
| SCHEMBL23937870 | 0.77 | KDM4E (0.38) | PTPN1L3MBTL1TDP1GAAMEN1 | |
| SCHEMBL20139203 | 0.76 | PTPN1 (0.43) | PTPN1L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL3583183 | 0.76 | GUCY1A1 (0.44) | GUCY1A1GUCY1B1KCNH2L3MBTL1TDP1 | |
| SCHEMBL20142239 | 0.74 | PTPN1 (0.41) | PTPN1L3MBTL1GAAMEN1KMT2A | |
| SCHEMBL20148879 | 0.70 | AR (0.41) | ARPTPN1GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL20148878 | 0.70 | PIM1 (0.43) | ARPTPN1GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL2743125 | 0.69 | CNR2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-110267658-B | Treatment of CNS disorders with sGC stimulators | 帝善多制药公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20190343813-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3538096-A1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089328-A1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343813-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | AR 4768/4885PTPN1 1161/4885GUCY1A1 4/4885 |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | GUCY1A2, GUCY1B2, PDE2A | AR 4768/4885PTPN1 1161/4885GUCY1A1 4/4885 |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | AR 4768/4885PTPN1 1161/4885GUCY1A1 4/4885 |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | PDE9A, PDE2A, GUCY1A2 | AR 4383/4885PTPN1 1468/4885GUCY1A1 9/4885 |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | AR 4768/4885PTPN1 1161/4885GUCY1A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.